These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2660932)

  • 21. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E; Marcopito LF; Zago MA
    Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current possibilities in the therapy of iron overload].
    Cermák J
    Vnitr Lek; 1994 Sep; 40(9):605-8. PubMed ID: 7975366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute renal insufficiency occurring during intravenous desferrioxamine therapy.
    Batey R; Scott J; Jain S; Sherlock S
    Scand J Haematol; 1979 Mar; 22(3):277-9. PubMed ID: 451459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
    Constantoulakis M; Economidou J; Karagiorga M; Katsantoni A; Gyftaki E
    Ann N Y Acad Sci; 1974; 232(0):193-200. PubMed ID: 4528481
    [No Abstract]   [Full Text] [Related]  

  • 27. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major.
    Richardson ME; Matthews RN; Alison JF; Menahem S; Mitvalsky J; Byrt E; Harper RW
    Aust N Z J Med; 1993 Dec; 23(6):656-61. PubMed ID: 8141693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes.
    Hathirat P; Areekul S; Isarangkura P; Chantachum Y
    J Med Assoc Thai; 1989 Jan; 72 Suppl 1():121-4. PubMed ID: 2732632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
    Krüger N; Ullrich D; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1985 Nov; 110(48):1848-51. PubMed ID: 4064938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y; Shaklai M; Liban E; Pinkhas J
    Isr J Med Sci; 1981 May; 17(5):348-51. PubMed ID: 7263191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR; Barnett MD; Brozovic B; Cattell WR; Ackrill P; McAlister J; Nimmon C
    Clin Nephrol; 1976 Jul; 6(1):326-8. PubMed ID: 954239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
    Anderson LJ; Wonke B; Prescott E; Holden S; Walker JM; Pennell DJ
    Lancet; 2002 Aug; 360(9332):516-20. PubMed ID: 12241655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron chelation.
    Hershko C; Pinson A; Link G
    Blood Rev; 1990 Mar; 4(1):1-8. PubMed ID: 2182144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H; Goshen J; Carmi D; Yaniv I; Kaplinsky C; Cohen IJ; Zaizov R
    Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of long-term iron-chelating therapy.
    Gabutti V; Piga A
    Acta Haematol; 1996; 95(1):26-36. PubMed ID: 8604584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferasirox.
    Stumpf JL
    Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C; Plantaz D
    Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
    Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.